Document is current
Any future updates will be listed below
-
Authors
Óskarsson, Jón Þórir https://orcid.org/0000-0002-9201-1166
Rögnvaldsson, Sæmundur https://orcid.org/0000-0003-2162-8414
Thorsteinsdottir, Sigrun https://orcid.org/0000-0001-5017-3530
Long, Thorir Einarsson https://orcid.org/0000-0003-2377-7886
Ólafsson, Andri
Eythorsson, Elias
Jónsson, Ásbjörn
Viðarsson, Brynjar
Önundarson, Páll T.
Agnarsson, Bjarni A.
Pálmason, Róbert
Sigurðardóttir, Margrét
Þorsteinsdóttir, Ingunn
Ólafsson, Ísleifur
Harding, Stephen J.
Durie, Brian G. M.
Love, Thorvardur Jon
Kristinsson, Sigurdur Y. https://orcid.org/0000-0002-4964-7476
-
Funding
Funding for this research was provided by:
International Myeloma Foundation (173857)
Icelandic Centre for Research (217897-051, 228521-051)
EC | Horizon 2020 Framework Programme (716677)
The Icelandic Cancer Society
- License Information
-
More Information
Article History
Received: 27 August 2024
Revised: 1 December 2024
Accepted: 4 December 2024
First Online: 18 December 2024
Competing interests
: SR has received honoraria for scientific talks by Siemens Healthineers and Johnson & Johnson. SÞ has received honoraria for scientific talks by Abbvie and Thermo Fisher Scientific. SH is an employee of The Binding Site. BGMD has done consultancy for Amgen, Janssen, Celgene, and Takeda. SYK has received research funding from Amgen and Celgene. The remaining authors declare no competing interests.
